Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$20.58

-1.38 (-6.28%)

16:07
11/04/19
11/04
16:07
11/04/19
16:07

Iovance Biotherapeutics reports Q3 EPS (40c), consensus (39c)

At September 30, 2019, the company held $367.3 million in cash, cash equivalents, short-term investments and restricted cash compared to $468.5 million at December 31, 2018. The company anticipates that the year-end balance of cash, cash equivalents, short-term investments and restricted cash may be between $310 and $320 million. "We continue making great progress in developing tumor infiltrating lymphocyte (TIL) therapy, which could become the first approved cell therapy product for solid tumor indications," commented Maria Fardis, Ph.D., MBA, president and chief executive officer of Iovance Biotherapeutics. "Our pivotal studies in metastatic melanoma and advanced cervical cancer are on track to complete enrollment in early 2020. We expect to submit for regulatory approval for TIL therapies lifileucel and LN-145 in late 2020. These therapies have the potential to impact the lives of thousands of patients in the U.S. with melanoma or cervical cancer that have exhausted current treatment options. Furthermore, we are very pleased to have a new IND active in order to investigate the polyclonal blood-based T cell, or PBL therapy (IOV-2001), in chronic lymphocytic leukemia (CLL). This candidate was developed based on Iovance research efforts focused on the generation of novel cell therapy products. We anticipate the initiation of IOV-CLL-01, an Iovance-sponsored trial with IOV-2001 PBL product, before the end of 2019."

  • 04

    Nov

  • 06

    Nov

IOVA Iovance Biotherapeutics
$20.58

-1.38 (-6.28%)

07/02/19
PIPR
07/02/19
NO CHANGE
Target $30
PIPR
Overweight
Iovance submission on track for second half of 2020, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro says guidance from the FDA, as announced this morning by the company, puts Iovance Biotherapeutics on track for a Biologics License Application in cervical cancer in the second half of 2020. This is a positive outcome and largely in-line with where consensus has moved following the ASCO presentation, Catanzaro tells investors in a research note. He maintains an Overweight rating on Iovance Biotherapeutics with a $30 price target.
07/02/19
HCWC
07/02/19
NO CHANGE
Target $32
HCWC
Buy
H.C. Wainwright reiterates Buy, $32 price target on Iovance
H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating on Iovance Biotherapeutics with a $32 price target after the company disclosed updates regarding the regulatory path for LN-145 in cervical cancer. With the possibility for innovaTIL-04 study to be registrational, the company is "reasonably" planning a path for a Biologics License Application submission in the second half of 2020, Pantginis tells investors in a research note. The analyst believes LN-145 "deserves the attention it is receiving." While the primary focus remains on Iovance's initial path to market with lifileucel in melanoma, LN-145 is a "potential rapid follower to commercialization," says Pantginis.
08/26/19
JEFF
08/26/19
NO CHANGE
Target $33
JEFF
Buy
Iovance pullback brings buying opportunity, says Jefferies
Jefferies analyst Biren Amin views the recent pullback in shares of Iovance Biotherapeutics as a buying opportunity into the end of 2019. After meeting with management, the analyst believes the melanoma and cervical pivotal cohorts appear to be enrolling patients with Iovance on track toward finishing patient enrollment in the melanoma study in Q1 of 2020. He thinks there is some likelihood of data at SITC in November and keeps a Buy rating on the shares with a $33 price target.
09/30/19
STFL
09/30/19
INITIATION
Target $27
STFL
Buy
Iovance Biotherapeutics initiated with a Buy at Stifel
Stifel analyst Benjamin Burnett started Iovance Biotherapeutics with a Buy rating and $27 price target. The analyst says his physician checks corroborate the view that the company's lifileucel and LN-145 data are "very good" and supportive of being the best therapeutic option in their respective advanced settings. He believes the market opportunity for an autologous tumor-infiltrating lymphocyte product in the advanced melanoma/cervical cancer setting can reach $2B-plus sales at peak.

TODAY'S FREE FLY STORIES

08:25
12/13/19
12/13
08:25
12/13/19
08:25
Conference/Events
Federal Reserve Bank of New York president participates in a discussion »

New York Federal Reserve…

FORM

FormFactor

$24.96

1.19 (5.01%)

, INTC

Intel

$57.56

0.52 (0.91%)

08:25
12/13/19
12/13
08:25
12/13/19
08:25
Recommendations
FormFactor, Intel, Samsung, TSMC analyst commentary  »

FormFactor price target…

FORM

FormFactor

$24.96

1.19 (5.01%)

INTC

Intel

$57.56

0.52 (0.91%)

SSNLF

Samsung

$0.00

(0.00%)

TSM

TSMC

$58.61

2.71 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 23

    Jan

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$47.44

1 (2.15%)

, FBHS

Fortune Brands

$65.51

0.31 (0.48%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Recommendations
Masco, Fortune Brands analyst commentary  »

Masco, Fortune Brands…

MAS

Masco

$47.44

1 (2.15%)

FBHS

Fortune Brands

$65.51

0.31 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$194.19

2.09 (1.09%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$88.89

0.9 (1.02%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$60.86

1.19 (1.99%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$32.84

0.58 (1.80%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Conference/Events
The FDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 08

    Mar

XLY

Consumer Discretionary Sector SPDR

$123.10

1.12 (0.92%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$60.92

0.85 (1.42%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$62.86

-0.32 (-0.51%)

08:22
12/13/19
12/13
08:22
12/13/19
08:22
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLP

Consumer Staples Sector SPDR

$62.54

-0.09 (-0.14%)

08:22
12/13/19
12/13
08:22
12/13/19
08:22
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$100.94

0.93 (0.93%)

08:22
12/13/19
12/13
08:22
12/13/19
08:22
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$163.97

1.4 (0.86%)

08:22
12/13/19
12/13
08:22
12/13/19
08:22
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$281.94

2.23 (0.80%)

08:21
12/13/19
12/13
08:21
12/13/19
08:21
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$317.06

2.65 (0.84%)

08:21
12/13/19
12/13
08:21
12/13/19
08:21
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$30.82

0.6 (1.99%)

08:21
12/13/19
12/13
08:21
12/13/19
08:21
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$359.70

7.3 (2.07%)

08:21
12/13/19
12/13
08:21
12/13/19
08:21
Recommendations
Tesla analyst commentary  »

Global demand for Teslas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 23

    Mar

SMH

Market Vectors Semiconductor

$140.37

3.99 (2.93%)

08:20
12/13/19
12/13
08:20
12/13/19
08:20
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

Invesco QQQ Trust

$206.52

1.54 (0.75%)

08:20
12/13/19
12/13
08:20
12/13/19
08:20
Technical Analysis
Invesco QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAC

ViacomCBS

$37.79

0.52 (1.40%)

, DIS

Disney

$146.85

0.03 (0.02%)

08:20
12/13/19
12/13
08:20
12/13/19
08:20
Initiation
ViacomCBS, Disney, Apple initiated  »

ViacomCBS initiated with…

VIAC

ViacomCBS

$37.79

0.52 (1.40%)

DIS

Disney

$146.85

0.03 (0.02%)

AAPL

Apple

$271.45

0.74 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$COMP

Nasdaq Composite

$0.00

(0.00%)

08:20
12/13/19
12/13
08:20
12/13/19
08:20
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDX

Nasdaq 100 Index

$0.00

(0.00%)

08:20
12/13/19
12/13
08:20
12/13/19
08:20
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.